Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Antimicrobial Susceptibility Testing Clinical Trial

Official title:
Antimicrobial Susceptibility Testing Guided Triple Therapy in Salvage Helicobacter Pylori Treatment

Status Not yet recruiting

Clinical Trial Summary

Helicobacter pylori (H. pylori), which infects about 50% of the global population, has been recognized as a main risk factor of multiple gastric pathologies, especially non-cardiac gastric cancer. Strongly evidence supports that H. pylori eradication is an effective approach to reduce the incidence of those pathologies.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Antimicrobial Susceptibility Testing
Disease Susceptibility
Triple Therapy

Clinical Trial Details

NCT number	NCT03139253
Study type	Interventional
Source	Shandong University
Contact	Li Yanqing, MD, PhD
Phone	86-531-82169236
Email	liyanqing@sdu.edu.cn
Status	Not yet recruiting
Phase	Phase 4
Start date	May 30, 2017
Completion date	June 30, 2017

View Details

See also
	Status	Clinical Trial	Phase
	Not yet recruiting	`NCT03571230` - Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication.	Phase 4
	Recruiting	`NCT02988089` - Antimicrobial Susceptibility Testing Guided Antibiotic Selection Strategies in Salvage Helicobacter Pylori Treatment	Phase 4